of disease severity than their counterparts who are treated in the outpatient setting. Therefore, in an otherwise healthy population of children diagnosed with CAP, it is unclear whether adjunct corticosteroids would be beneficial in fighting the infection or whether it would impair immune function and delay clearance of infection. The objective of this multicenter analysis was to determine whether the addition of corticosteroid therapy to standard antibiotic management is associated with decreased rates of treatment failure among children presenting with CAP in the ambulatory setting.
METHODS

Data Source
This retrospective cohort study enrolled patients from the outpatient pediatric practices affiliated with the Geisinger Health System (GHS), which provides primary care to a 31-county region in Central and Northeastern Pennsylvania. The primary care population of the GHS is similar to the regional resident population. The predominantly rural area is served by over 50 primary care clinics and 3 acute care hospitals. The Geisinger Health System uses EpicCare Electronic Health Records (EHR) (Epic Systems Corporation, Verona, WI) for all of their primary care and specialty clinic appointments, urgent care and emergency department (ED) visits, and hospitalizations. This integrated records system allows for thorough data collection at initial and follow-up visits from any site (eg, at their primary care clinic or the ED) within the GHS. This study has been approved by the Cincinnati Children's Hospital Medical Center and GHS Institutional Review Boards with a waiver of informed consent.
Patients
Children, ages 1-18 years, whose index visit within the GHS network was during January 1, 2008 to January 31, 2010 and had an initial clinical diagnosis of CAP in the outpatient setting were eligible for this study. An episode of CAP was defined as 14 days from the index visit; therefore, the same subject may have contributed more than 1 episode. However, repeated subjects occurred in only 8% of the patients in our total cohort of patients, the majority of which had 2 episodes of pneumonia within the study time frame. Because each episode of pneumonia had the potential for different treatment disease, the episodes were analyzed as unique observations. Subjects were included if they had a diagnosis of CAP identified by ICD-9 CM diagnosis codes (480, 482.3, 482.8, 482.9, 483, and 486) and verified by EHR review based on the documented presence of signs and symptoms of lower respiratory tract infection (eg, fever, rales, wheezing, retractions) and a physician diagnosis of CAP.
Children with immunocompromising conditions (eg, primary immune deficiency) or chronic medical conditions other than asthma that predispose them to severe or recurrent CAP (eg, cystic fibrosis) were excluded (n = 100) using a previously reported classification method [9] . Children less than 1 year of age were excluded to minimize misclassification of bacterial pneumonia, because these children experience a higher rate of viral respiratory infections (eg, bronchiolitis) that can be difficult to distinguish clinically from bacterial pneumonia. In addition, patients who did not receive antibiotics (n = 375) or who received antibiotics (eg, doxycycline) inconsistent for treatment of CAP (n = 98) when initially diagnosed with pneumonia were excluded because it is more likely that these patients were either suspected of having a viral etiology or were receiving antibiotics for another reason, respectively.
Children with asthma were identified as having had an ICD-9 diagnosis code of 493-494 during any outpatient visit before the initial date of diagnosis for CAP. Inhaled corticosteroids (eg, budesonide) given at the time of diagnosis for CAP were included as a separate variable. Due to the higher prevalence of respiratory infections from November through March in the Northeastern United States, we defined respiratory season as the occurrence of the initial diagnosis of CAP within that time period.
Treatment Measures
The primary exposure for this study was the receipt of adjunct systemic corticosteroid therapy at the initial visit when CAP was diagnosed. Adjunct systemic corticosteroid therapy was defined by receipt of methylprednisone, dexamethasone, prednisone, or prednisolone.
Measured Outcome
The primary outcome measure for this study was treatment failure. Treatment failure was defined as a respiratory disease-associated follow-up visit accompanied by a change in antibiotic therapy within 14 days of diagnosis, either in the outpatient setting, in the ED, or during a hospital admission. Respiratory disease-associated follow-up visit ICD-9 CM diagnosis codes included acute respiratory infections, tachypnea, cough, chest pain, and wheezing (465.9, 786.06, 786.2, 786.50, and 786.07, respectively). Scheduled follow-up (eg, referrals) or follow-up at specialty clinics were excluded.
Data Analysis
Categorical variables were described using counts and frequencies and were compared across treatment groups using χ 2 tests. Because pneumonia can lead to increased wheezing in children with a history of asthma and presentation with wheezing is more likely to result in prescription of adjunct systemic corticosteroid therapy, the total cohort was stratified by asthma status to limit confounding by indication [10, 11] . Within each strata, a propensity score model was created because there were many variables that clinicians likely considered when prescribing adjunct corticosteroid therapy for CAP in the context of relatively few outcomes (ie, treatment failures). Propensity score analysis reduces the number of parameters needed in a multivariable model for proper adjustment when there are relatively few outcomes [12] . Matching treatment groups by propensity score allows for treatment groups to be balanced with respect to multiple covariates that are predictors of treatment and may also be determinants of treatment failure, thus eliminating or reducing confounding at the study design stage. The propensity score estimated the probability of being prescribed adjunct corticosteroid therapy given a set of baseline potential predictors: age, sex, race, insurance, respiratory complaint documented (eg, cough, shortness of breath), receipt of albuterol, fever, season of diagnosis, wheezing, crackles, retractions present at initial diagnosis, antibiotic therapy received at initial diagnosis, chest x-ray performed, and an interaction term between antibiotic received and wheezing at presentation. The final propensity score model's calculated c statistics were 0.80 in the stratum without a history of asthma and 0.72 in the stratum with a history of asthma, which represent good and adequate predictive accuracy, respectively [13] . The following matching scheme was used to maximize covariate balance between treatment groups as well as sample size: among patients with no history of asthma, those who received systemic corticosteroids were matched without replacement with patients who did not receive corticosteroids using a caliper of 0.04 (difference in the predicted probability of assignment to corticosteroids between a patient actually receiving corticosteroids and the matched patient who did not receive such treatment) using a 1:7 matching ratio; whereas among patients with history of asthma, those who received systemic corticosteroids were matched without replacement with patients who did not receive corticosteroids using a caliper of 0.04, using a 1:1 matching ratio [14, 15] . The CochranMantel-Haenszel test was used to evaluate balance of the matching procedure [16] . Specified calipers were chosen in each stratum to obtain optimum balance within the heterogeneous groups.
To evaluate the effect of adjunct corticosteroid therapy on treatment failure, relative risks and their 95% confidence intervals (CIs) were estimated from log-odds ratios (ORs), and their standard errors were estimated by conditional logistic regression models specifying treatment failure as a binary dependent variable and adjunct corticosteroid treatment as a binary independent variable. Adjusted matched models for practice location yielded nearly identical estimates; therefore, we only present results for the matched models described above. Statistical tests were considered significant when the corresponding P value was smaller than the conventional value of .05. All statistical analyses were performed using SAS statistical software (version 9.2; SAS Institute Inc., Cary, NC).
RESULTS
Study Cohort
There were 2244 patients in the cohort. School-aged children, 6-18 years old, comprised over half the cohort (n = 1212; 54%); most patients were white (89%) and had private insurance (69%). Patients with no history of asthma made up 77% (n = 1727) of the total cohort (Table 1) . Within this stratum, adjunct corticosteroid therapy was prescribed to 86 (5%) patients, and approximately half of these patients presented with wheezing (n = 42; 49%). A history of asthma was documented in 517 children (23%). Within this group, 207 (40%) received adjunct corticosteroid therapy; among these, wheezing was present in over half of the children (n = 127, 61%). Most patients (1329 of 2244; 59%) were treated with macrolide monotherapy for their CAP diagnosis; differences in receipt of macrolide monotherapy were not significant between corticosteroid recipients and nonrecipients in either stratum (Table 1) . Propensity score-matching within stratum balanced the groups with regard to demographics, clinical signs and symptoms, and treatment (Table 2 ). Once matched, there were no statistically significant differences between treatment groups in children with a history of asthma; however, retractions remained statistically different between treatment groups in children without a history of asthma (Table 2) .
Treatment Failure
Within 14 days of their initial CAP diagnosis, 105 of 2244 patients (5%) experienced treatment failure (Table 3) . Hospitalization occurred in 2 cases (1.9%), both in the group with no history of asthma, and no additional patients received ED evaluation. In the overall matched model, we found no statistically significant difference in treatment failure in patients who received adjunct corticosteroids (OR, 1.72; 95% CI, 0.93 and 3.19) ( Table 4) .
Among patients with no history of asthma, patients who were treated with adjunct corticosteroids had over twice the risk of failing treatment in unadjusted analysis as those who did not receive adjunct corticosteroids. In the propensity-matched analysis, patients who received adjunct corticosteroid therapy had 2-fold higher odds of failing treatment compared with patients who did not receive adjunct corticosteroids (OR, 2.38; 95% CI, 1.03 and 5.52) ( Table 4) .
Among patients with a history of asthma, 17 patients (3%) failed treatment (Table 3) . Those who received adjunct corticosteroid therapy had higher odds of failing treatment compared with patients who did not receive adjunct corticosteroids; however, this association was not statistically significant (OR, 1.12; 95% CI, .43 and 2.92) ( Table 4) .
DISCUSSION
This multicenter retrospective study examined the association of adjunct systemic corticosteroid therapy in children diagnosed with CAP in the outpatient setting. Among children without asthma, adjunct corticosteroid therapy was associated with an increase in treatment failure for CAP; in contrast, there were no statistically significant differences in treatment failure between corticosteroid recipients and nonrecipients with underlying asthma. Our findings suggest that in children without an underlying condition of asthma, adjunct corticosteroid therapy is not beneficial for CAP and may increase the likelihood of treatment failure.
Corticosteroids inhibit the migration of neutrophils from blood vessels and down-regulate many proinflammatory cytokines released during acute infection [3, 17, 18] . Because corticosteroids may reduce inflammatory activation, they may serve as an important adjunct therapy for CAP in children with asthma. In children without asthma, the addition of corticosteroid therapy for CAP may be harmful by blunting the inflammatory response to infection, thereby limiting the ability of the immune system to combat the infection [8] . However, the use of corticosteroid therapy in childhood CAP in the outpatient setting is not well studied, as evidenced by the Pediatric Infectious (2) 23 (1) 4 (5) 7 (2) 8 (4) Diseases Society/Infectious Diseases Society of America joint national guideline published in 2011, which does not address the role of adjunct corticosteroid therapy [19] . Previous studies in hospitalized patients have focused on wheezing, possibly as a surrogate for increased inflammation of the lung tissue. Wheezing can be present in children diagnosed with CAP for 2 potential reasons: (1) an underlying condition of asthma or (2) infection with an atypical bacteria, such as M pneumoniae. However, multiple studies in both hospitalized adults and children have demonstrated limited benefits of prescribing adjunct corticosteroid therapy to patients who present with wheezing in the context of pneumonia [7, 8] . Among hospitalized children diagnosed with CAP who received β-agonist therapy, which was used as a proxy for patients who wheezed at the time of hospitalization, length of stay was shorter among patients who received adjunct corticosteroid therapy compared with those who did not [7] . The lack of a statistical benefit of corticosteroids among children with a history of asthma in our study, who proportionally were most likely to present with wheezing, is possibly due to their less severe case of CAP compared with those who required hospitalization, as in the previous study. Hospitalized patients may have a more prolonged and greater inflammatory response to CAP on top of the inflammation present from wheezing, compared with more mild cases that present in an outpatient setting that did not require an ED visit or hospitalization.
Weiss et al. [7] found that hospitalized patients who received corticosteroid therapy but not β-agonist therapy were at higher odds of being readmitted within 28 days of their initial hospitalization. This finding is similar to ours in which patients with no history of asthma who received adjunct corticosteroid therapy were more likely to fail treatment compared with those who did not receive corticosteroid therapy. These data suggest that outpatients with CAP who do not present with wheezing or who do not have a history of asthma regardless of severity of disease do not benefit from adjunct corticosteroid therapy and are more likely to experience treatment failure.
There were several limitations to our study. First, only children who received antibiotic therapy for their course of pneumonia and who were older than 1 year were included, to minimize misclassification of bacterial pneumonia. Therefore, this study cannot be generalized to children who are diagnosed with a suspected viral pneumonia, have a history of asthma, or present with wheezing. However, there is ample evidence supporting the lack of benefit of corticosteroids in young children with lower respiratory tract infections of suspected viral origin [10] . Second, there may be confounding by indication for children who received adjunct corticosteroid therapy related to more severe illness at time of presentation. We included potential markers of severity (eg, rales, retractions, chest radiograph performed) in the propensity score to account for severity of illness, and we excluded patients with chronic complex conditions. In addition, propensity score matching was used in this analysis to minimize confounding by indication. Nevertheless, residual or unmeasured confounding cannot be completely ruled out. Third, there are no specific codes to indicate an unscheduled follow-up visit in this dataset. All diagnosis codes for patients who had a return visit in the outpatient setting, ED, or who were hospitalized were classified as a follow-up visit for a respiratory illness within 14 days of the initial CAP diagnosis or not. Therefore, we created a conservative definition of treatment failure that also required a change in antibiotic therapy at the follow-up visit. This approach caused us to overestimate treatment failure rates if patients with drug-related complications were also coded with a respiratory illness code at the time their antibiotic was changed.
However, there is no reason to suspect that this coding would occur differentially between corticosteroid recipients and nonrecipients. Furthermore, overall treatment failure rates were relatively low. Fourth, we cannot directly account for the accuracy of treatment because microbiological data regarding the etiology of disease was not available for the patients in this study. Testing for bacterial causes of pneumonia (eg, Streptococcus pneumoniae or M pneumoniae) are not routinely performed in the outpatient setting and, even when performed, such testing rarely yields an etiology. Furthermore, the goal of this study was not to determine the accuracy of antibiotic treatment but rather to determine effectiveness of corticosteroids in improving outcomes for children with pneumonia while accounting for potential confounders such as type of antibiotic treatment. Lastly, patients in our study were under the care of 1 health system, all had medical insurance coverage, and all were predominantly white and from a suburban and rural setting, thereby limiting the generalizability of our findings.
As one of the largest outpatient pediatric studies conducted, data from over 2000 patients from over 50 primary care clinics were used to evaluate the potential treatment benefits of adjunct corticosteroid therapy among patients with and without a history of asthma [8] . By using propensity score matching, we were able to balance treatment groups and found no statistical benefit of adjunct corticosteroid therapy among children with a history of asthma. In addition, children without a history of asthma who received adjunct corticosteroid therapy were more likely to fail treatment within 14 days of their initial diagnosis of CAP than children who did not receive adjunct corticosteroid therapy.
